According to the Physician’s Association for Anthroposophic Medicine:
“Anthroposophically extended medicine brings deeper insights into the care of the whole human being. It is practiced by conventionally trained physicians and nurses who have undergone additional specialized training, learning to apply a broad array of effective natural medicines. This whole person approach also incorporates art, music, movement and massage therapies as elements of collaborative, multidisciplinary healthcare. “
Mistletoe treatment is considered such a therapy. The conventional medical community is becoming increasingly aware that it doesn’t have all the answers, in particular with regard to cancer. More integrative approaches are making their way into treatment protocols and more decision-making power is being given to patients.
I am presently reading a book entitled, Mistletoe and the Emerging Future of Integrative Oncology. In this post, I will share what I’ve learned. Although mistletoe is one of the most researched integrative cancer treatments in Western Europe, and there have been 150 published clinical studies on mistletoe therapy, it is still a lesser- known offering in North America. Mistletoe therapy while safe and effective requires very specific training.
Mistletoe extract has been widely used to support cancer therapy and improve quality of life, but there has been a lack of clinical trials and data to support its use. Researchers at the Johns Hopkins Kimmel Cancer Center completed what is believed to be the first phase I trial of intravenous Helixor M in the U.S. aimed at determining dosing for subsequent clinical trials and to evaluate safety.
The findings from the small study were reported online Feb. 9 in Cancer Research Communications 1. According to the same source, 160 studies have been conducted on the anthroposophical mistletoe preparations abnobaVISCUM, Helixor, Iscador and Iscucin as of March 2023, including 34 prospective randomised controlled clinical trials (RCTs)